Dimensional Fund Advisors’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-154,456
| Closed | -$246K | – | 3446 |
|
|
2024
Q1 | $246K | Hold |
154,456
| – | – | ﹤0.01% | 3161 |
|
|
2023
Q4 | $133K | Sell |
154,456
-53,442
| -26% | -$46.9K | ﹤0.01% | 3251 |
|
|
2023
Q3 | $222K | Sell |
207,898
-230,635
| -53% | -$477K | ﹤0.01% | 3199 |
|
|
2023
Q2 | $1.14M | Sell |
438,533
-25,365
| -5% | -$90.5K | ﹤0.01% | 2905 |
|
|
2023
Q1 | $1.89M | Sell |
463,898
-83,967
| -15% | -$388K | ﹤0.01% | 2755 |
|
|
2022
Q4 | $2.75K | Sell |
547,865
-239,943
| -30% | -$1.5M | ﹤0.01% | 2631 |
|
|
2022
Q3 | $10.3M | Buy |
787,808
+141,090
| +22% | +$2.14M | ﹤0.01% | 2144 |
|
|
2022
Q2 | $8.29M | Buy |
646,718
+87,379
| +16% | +$1.21M | ﹤0.01% | 2269 |
|
|
2022
Q1 | $8.53M | Buy |
559,339
+125,732
| +29% | +$1.96M | ﹤0.01% | 2360 |
|
|
2021
Q4 | $7.68M | Buy |
433,607
+191,886
| +79% | +$3.68M | ﹤0.01% | 2412 |
|
|
2021
Q3 | $5.08M | Buy |
241,721
+114,164
| +90% | +$2.51M | ﹤0.01% | 2577 |
|
|
2021
Q2 | $2.52M | Sell |
127,557
-17,707
| -12% | -$414K | ﹤0.01% | 2815 |
|
|
2021
Q1 | $4.21M | Buy |
145,264
+74,332
| +105% | +$2.08M | ﹤0.01% | 2634 |
|
|
2020
Q4 | $2.15M | Buy |
70,932
+22,500
| +46% | +$492K | ﹤0.01% | 2788 |
|
|
2020
Q3 | $771K | Buy |
48,432
+37,116
| +328% | +$677K | ﹤0.01% | 2988 |
|
|
2020
Q2 | $223K | Buy |
+11,316
| New | +$216K | ﹤0.01% | 3202 |
|
Dimensional Fund Advisors's NGM Position: Q2 2024 in Review
Dimensional Fund Advisors sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q2 2024, closing a stake of 154,456 shares — an estimated $246K sold.
Dimensional Fund Advisors first reported a position in NGM in Q2 2020 and held it in 16 quarters. The position peaked at $10.3M in Q3 2022. 0 funds tracked by Wall St. Rank hold NGM as of Q2 2024.
- Dimensional Fund Advisors reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
- Dimensional Fund Advisors sold 154,456 NGM Biopharmaceuticals, Inc. Common Stock shares in Q2 2024, an estimated $246K.
- Dimensional Fund Advisors first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q2 2020 and held it in 16 quarters.
- Dimensional Fund Advisors's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $10.3M in Q3 2022.
- 0 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q2 2024.
Based on Dimensional Fund Advisors's 13F filing for Q2 2024, filed 9 Aug 2024.